The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases
The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases
Podcast Description
AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer's, Parkinson’s, and related neurodegenerative diseases. The "AD/PD™ Session Spotlight" series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes.
Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.
Podcast Insights
Content Themes
The podcast centers on neurodegenerative diseases, particularly Alzheimer's and Parkinson's, covering areas like regulatory philosophies, approval processes, biomarker developments, and clinical implications. Recent episodes discuss topics such as varying regulatory approaches to drug approvals across different regions and the role of biomarkers in treatment selection, reflecting the latest research presented at the AD/PD™ 2025 Conference.
AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. The “AD/PD™ Session Spotlight” series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes.
Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.
In this episode, we explore Plenary Lecture 2 from the AD/PD™ 2025 International Conference: “GLP-1R Agonist Effects in Brain.”
Moderated by Dr. Cynthia Lemere (USA) and Dr. Henrietta Nielsen (Sweden), this featured lecture was presented by Dr. Lotte Bjerre Knudsen (Denmark), Chief Scientific Advisor at Novo Nordisk. A pioneering force in GLP-1 drug development and co-inventor of liraglutide, Dr. Knudsen shared novel data on semaglutide’s potential neuroprotective mechanisms, as the drug advances through Phase 3 trials (EVOKE & EVOKE+) for Alzheimer’s disease.
Key highlights include:
• GLP-1’s dual role as a hormone and neurotransmitter with CNS effects
• Evidence that semaglutide dampens hippocampal inflammation and supports microglial homeostasis
• Insights into how GLP-1R agonists may stabilize plaques and modulate APOE-related pathways
• Potential applications for GLP-1 drugs beyond metabolic disorders, including AD and neurodegeneration
• How cardiovascular and anti-inflammatory benefits seen in obesity and diabetes may translate to brain health
This episode is especially relevant for neurologists, neuroscientists, translational researchers, pharmaceutical professionals, and anyone interested in repurposing metabolic therapies for neurodegenerative diseases.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.